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Abstract
Background and aims: Steatosis and insulin resistance (IR) are the major
disease modifying in patients with chronic hepatitis C (CHC). Only
few studies evaluated these features in patients with chronic hepatitis B
(CHB). We aimed to assess the prevalence and the factors related to steatosis
and IR in CHB patients, compared with CHC subjects, and to evaluate the
potential association between these features and fibrosis severity.Material and
methods: One hundred and seventy consecutive patients with CHB (28
HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and
metabolic measurements and matched for sex, age and body mass index with
170 genotype 1 CHC patients. IR was defined if HOMA-IR4 2.7. All biopsies
were scored for grading and staging by Scheuer’s score, and the steatosis was
considered significant if Z10%. Results: The prevalence of significant stea-
tosis was similar in both CHB and CHC patients (31 vs. 38%; P= 0.14). IR rate
was significantly higher in CHC than in CHB patients (42 vs. 26%; P= 0.002).
Severe fibrosis (F3–F4), at multivariate analysis, was independently associated
with older age (OR 1.050, 95% CI 1.009–1.093), steatosis 4 10% (OR 4.375,
95% CI 1.749–10.943), and moderate–severe necroinflammatory activity (OR
8.187, 95% CI 2.103–31.875), regardless of HBeAg status, in CHB patients,
and with older age (OR 1.080, 95% CI 1.028–1.136), IR (OR 2.640, 95% CI
1.110–6.281), steatosis 4 10% (OR 3.375, 95% CI 1.394–8.171), and moder-
ate–severe necroinflammatory activity (OR 8.988, 95% CI 1.853–43.593) in
CHC patients. Conclusions: CHB patients had high steatosis prevalence,
similar to CHC controls, but lower IR rate. Both steatosis and IR in CHC,
and only steatosis in CHB, are independently associated with fibrosis severity.
Steatosis and insulin resistance (IR) are the key findings
in patients with nonalcoholic fatty liver disease (NAFLD)
(1). Similarly, in patients with chronic hepatitis C
(CHC), where HCV seems able to directly interfere with
mechanisms leading to steatosis and IR (2, 3), these
features represent two frequent findings able to nega-
tively influence the severity of liver disease (4–6) and the
likelihood of response to antiviral therapy (4, 7). Instead
only few studies evaluated the prevalence and the role of
both steatosis and IR in patients with chronic hepatitis B
(CHB).
Some studies, performed in population different for
ethnicity, demographical, clinical and metabolic factors,
reported a prevalence of steatosis in CHB patients ran-
ging from 4.5 to 71%, observing that fat accumulation
was independently associated with metabolic factors,
such as high body mass index (BMI), dislipidaemia, IR
and diabetes (8–32). In addition, these studies did not
find any association between steatosis and viral factors,
and did not identify steatosis as an independent risk
factor for severity of fibrosis in CHB patients.
Contrasting results reported similar or lower IR rate in
HBV patients compared with HCV subjects (14, 29–31,
33, 34), and similar or higher IR rate in HBV patients
compared with healthy controls (26, 28, 35, 36), even if
no data showed an association between viral character-
istics of HBV and IR. Interestingly only two of these
studies identified IR (32) and the metabolic syndrome
(37), the clinical expression of IR, as significant risk
factors for cirrhosis.
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Therefore, the aims of this study were to assess the
prevalence and the factors associated with steatosis and
IR in CHB patients, compared with matched CHC
subjects, and to evaluate the potential association be-
tween these features and severity of fibrosis.
Materials and methods
Patients
This study was carried out on a sample of 170 consecu-
tive patients with CHB, recruited at the GI & Liver Unit
of the University Hospital in Palermo, between January
2000 and December 2008. Patients were included if they
had abnormal alanine aminotransferase (ALT) from at
least 6 months, HBV-DNA4 2000 IU/ml, and a histolo-
gical diagnosis of CHB with any degree of fibrosis,
including cirrhosis. As control group we selected a cohort
of 170 G1 CHC patients matched for sex, age and BMI,
observed in the same period of time, and characterized
by the presence of anti-HCV and HCV-RNA, and with a
liver histology of chronic hepatitis (any degree of fibrosis,
including cirrhosis).
Exclusion criteria were: (i) advanced cirrhosis (Child–
Pugh B and C); (ii) hepatocellular carcinoma; (iii) other
causes of liver disease or mixed aetiologies; (iv) alcohol
consumption 4 20 g/die in the last 6 months below the
biopsy, evaluated by patient history; (v) HIV infection;
(vi) previous treatment with antiviral therapy in the last
years before liver biopsy; previous treatment with
immunosuppressive drug and/or regular use of steato-
sis-inducing drugs; (vii) previous diagnosis of type 1
diabetes mellitus; (viii) active IV drug addiction.
This study was performed in accordance with the
principles of the Declaration of Helsinki, and its appen-
dices, and with local and national laws. Approval was
obtained from the hospital’s Internal Review Board and
the Ethical Committee, and written informed consent
from all patients and controls.
Clinical and laboratory assessment
Clinical and anthropometric data were collected at the
time of liver biopsy. BMI was calculated on the basis of
weight in kilograms and height (in metres). and subjects
were classified as normal weight (BMI, 18.5–24.9 kg/m2),
overweight (BMI, 25–29.9) and obese (BMI4 30).
The diagnosis of type 2 diabetes was based on the
revised criteria of the American Diabetes Association
using a value of fasting blood glucose ofZ126mg/dl on
at least two occasions (38). In patients with a previous
diagnosis of type 2 diabetes, current therapy with oral
hypoglycaemic agents was documented.
A 12-h overnight fasting blood sample was drawn at
the time of biopsy to determine serum levels of ALT, total
cholesterol, triglycerides and plasma glucose concentra-
tion. Serum insulin was determined using a two-site
enzyme ELISA (Mercodia Insulin ELISA, Arnika). IR
was determined by the homeostasis model assessment
(HOMA) method, using the following equation (39):
Insulin resistance (HOMA-IR) = Fasting insulin (mU/
ml) Fasting glucose (mmol/L)/22.5. HOMA-IR has
been validated in comparison with the euglycaemic/
hyperinsulinaemic clamp technique in both diabetic and
nondiabetic subjects (40). HOMA-IR values 4 2.7 were
considered to indicate IR; this cut-off corresponds to the
upper quartile of a previously published control Italian
population (41).
Hepatitis B virus-infected patients were tested at the
time of biopsy for HBs, HBeAg, anti-HBe and anti-HDV
IgG, using commercial enzyme immunoassays (Dia Sorin,
Saluggia, Italy). HBV-DNA was quantified by bDNA
(Versant HBV 3.0, Siemens Medical Solutions Diagnostics
Europe, Dublin, Ireland; range 357–17 857 000 IU/ml).
HCV-infected individuals were tested at the time of biopsy
for HCV-RNA using qualitative PCR (Cobas Amplicor
HCV Test version 2.0; limit of detection: 50 IU/ml). HCV-
RNA-positive samples were quantified by Versant
HCV-RNA 3.0 bDNA (Bayer Co. Tarrytown, NY, USA)
expressed in IU/ml. Genotyping was performed by INNO-
LiPA (HCV II, Bayer HealthCare, Berkeley, CA, USA).
Assessment of histology
Slides were coded and read by a single pathologist (D. C.)
unaware of the patient’s identity and history. A mini-
mum length of 15mm of biopsy specimen or the
presence of at least 10 complete portal tracts was required
(42). Biopsies were classified according to the Scheuer
numerical scoring system (43).
The percentage of hepatocytes containing fat was
determined for each  10 field. An average percentage
of steatosis was then determined for the entire specimen.
Steatosis was assessed as the percentage of hepatocytes
containing fat droplets (minimum, 5%), and evaluated
as continuous variable. Steatosis was also classified as:
mild 4 5 to o 10%, moderate/severeZ10%.
Statistics
Continuous variables were summarized as mean SD
and categorical variables as frequency and percentage.
Multiple logistic regression models were used to assess
the relationship of fibrosis, steatosis, necroinflamatory
activity and IR to demographical, virological, metabolic
and histological characteristics of patients, in both CHB
and CHC patients. In the first model, the dependent
variable was fibrosis coded as 0 = F1–F2; or 1 = F3–F4. As
candidate risk factors for severe fibrosis (F3–F4) we
selected age, gender, BMI, baseline ALT, total cholesterol,
triglycerides, blood glucose, insulin, HOMA score, IR,
diabetes, HBV-DNA levels (for HBV patients), virologi-
cal status (for HBV patients), HCV-RNA levels (for HCV
patients), steatosis 4 10%, and moderate–severe ne-
croinflammatory activity. In the second model, the
dependent variable was steatosis coded as 0  10%; or
1Z10%. In the third model, the dependent variable was
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necroinflammatory activity coded as 0 =mild; or
1 =moderate–severe. In the fourth model, the depen-
dent variable was IR coded as 0 =HOMA  2.7; or
1 =HOMA4 2.7.
Variables found to be associated with the dependent
variable at univariate analyses (probability threshold,
P  0.10) were included in multivariate regression mod-
els. To avoid the effect of the co-linearity, diabetes, IR,
HOMA-score, blood glucose levels and insulin levels,
were not included in the same multivariate model.
Similarly we did not include necroinflammatory activity
and ALT levels in the same multivariate model. Regres-
sion analyses were performed using PROC LOGISTIC, PROC
REG and subroutine in SAS (SAS Institute Inc., Cary, NC,
USA) (44).
Results
Patients’ features and histology
Baseline features of HBV and HCV patients are shown in
Table 1. Obesity was identified in about 10% of cases in
both groups. IR rate was significantly higher in CHC than
in CHB patients (42.2 vs. 25.9%; P= 0.002), as well as type
2 diabetes (8.8 vs. 3.6%; P= 0.04). At liver biopsy the
prevalence of steatosis was similar in both CHB and CHC
patients (40 vs. 47%), and a moderate–severe grade was
identified in approximately 30–40% of the cases in both the
groups. In particular, steatosisZ30% was found in 11.2%
of HBV (19/170), compared with 14.7% (25/170) of HCV
patients (P= 0.33). Severe fibrosis was found in about a
quarter of cases in both HCV- and HBV-infected patients.
Table 1. Demographical, laboratory, metabolic, virological and histological features of 340 patients with chronic hepatitis B and genotype 1
chronic hepatitis C
Variable Chronic hepatitis B (n= 170) Chronic hepatitis C (n= 170) P
Mean age (years) 40.2 14.0 42.5 10.3 0.11
Gender
Male/female 121 (71.2)/49 (28.8) 121 (71.2)/49 (28.8) 1.00
Virological status
HBeAg positive 28 (16.5)
Anti-HBe positive 142 (83.5) – –
Log10HBV-DNA 4.91.5 – –
Log10HCV-RNA – 5.50.6 –
Mean body mass index (kg/m2) 25.5 3.5 25.8 3.6 0.54
Body mass index (kg/m2)
o 25 70 (41.2) 65 (38.2)
25–29.9 79 (46.5) 88 (51.8)
Z30 21 (12.3) 17 (10.0)
Type 2 diabetes
Absent/present 164 (96.4)/6 (3.6) 155 (91.2)/15 (8.8) 0.04
Alanine aminotransferase (IU) 102.997.3 92.6 74.8 0.27
Cholesterol (mg/dl) 190.544.4 171.137.8 o 0.001
Triglycerides (mg/dl) 101.053.8 106.270.3 0.49
Blood glucose (mg/dl) 90.5 20.1 90.2 23.0 0.80
Insulin (mU/ml) 10.4 7.1 12.3 8.1 0.02
HOMA score 2.38 1.81 2.78 1.80 0.04
Insulin resistance (HOMA4 2.7)
Absent/present 126 (74.1)/44 (25.9) 100 (58.8)/70 (42.2) 0.002
Histology at biopsy
Steatosis
Absent (o5%) 102 (60.0) 90 (52.9)
Present (Z5%) 68 (40) 80 (47.1) 0.19
Absent/mild (o10%) 117 (68.8) 104 (61.2)
Moderate/severe (Z10%) 53 (31.2) 66 (38.8) 0.14
Stage of fibrosis
1 65 (38.2) 55 (32.4)
2 61 (35.8) 75 (44.1)
3 26 (15.3) 30 (17.6)
4 18 (10.7) 10 (5.9) 0.95
Grade of activity
1 53 (31.2) 42 (24.7)
2 64 (37.6) 100 (58.8)
3 53 (31.2) 28 (16.5) 0.25
14 patients were anti-HDV positive.
HOMA, homeostasis model assessment; HCV-RNA, hepatitis C virus ribonucleic acid; HBV-DNA, hepatitis B virus deoxyribonucleic acid.
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Among HBV patients 28 (16.5%) were HBeAg
positive, and 142 (83.5%) anti-HBeAg positive (14 of
them anti-HDV positive). HBeAg- compared with
anti-HBe-positive patients were younger (Po 0.001),
had higher HBV-DNA viral load (Po 0.001) and ALT
levels (Po 0.001) and had a lower prevalence of signifi-
cant steatosis (P= 0.03) and severe fibrosis (P= 0.01).
Factors associated with moderate–severe steatosis
The univariate and multivariate comparison of variables
between patients with and without moderate–severe
steatosis (Z10%) is reported in Table 2, for both HBV
and HCV patients. Multivariate logistic regression analy-
sis (Table 2, top) showed that the following features were
independently linked to moderate–severe steatosis
(Z10%) in HBV patients: older age (OR 1.043, 95% CI
1.011–1.076, P= 0.009), male gender (OR 0.298, 95%
CI 0.111–0.805, P= 0.01), high BMI (OR 1.136, 95%
CI 1.005–1.284, P= 0.04) and IR (OR 3.815, 95% CI
1.700–8.560, P= 0.001). After the exclusion of 28
HBeAg-positive patients we obtained results similar to
the exclusion of 14 anti-HDV-positive patients (data not
shown).
In patients with CHC, we confirmed high BMI (OR
1.146, 95% CI 1.034–1.271, P= 0.009), and IR (OR 2.761,
95% CI 1.386–5.500, P= 0.004) as the only variables
independently linked to moderate–severe steatosis (Table
2, bottom).
Factors associated with IR
Multivariate logistic regression analysis showed that the
following features were independently linked to IR
(HOMA4 2.7) in CHB patients: high BMI (OR 1.167,
95% CI 1.028–1.324, P= 0.01), and moderate–severe
steatosis (OR 2.705, 95% CI 1.169–6.257, P= 0.02). After
the exclusion of 28 HBeAg-positive patients we obtained
results similar to the exclusion of 14 anti-HDV-positive
patients (data not shown).
In patients with CHC, we found that high triglycerides
levels (OR 1.014, 95% CI 1.005–1.022, P= 0.002), mod-
erate–severe steatosis (OR 2.596, 95% CI 1.236–5.454,
P= 0.01) and severe fibrosis (OR 2.571, 95% CI
1.061–6.228, P= 0.03) were independently associated
with IR.
Considering the higher prevalence of IR observed in
CHC patients compared with CHB subjects we per-
formed a logistic model for IR including together all
HBV and HCV patients, and evaluating aetiology as an
additional dependent variable. Univariate and multivari-
ate analysis (Table 3) showed that IR was independently
associated with high BMI (OR 1.108, 95% CI
1.023–1.201, P= 0.01), high triglycerides levels (OR
1.006, 95% CI 1.001–1.011, P= 0.02), moderate–severe
steatosis (OR 2.431, 95% CI 1.420–4.164, P= 0.001),
severe fibrosis (OR 2.636, 95% CI 1.415–4.912,
P= 0.002) and HCV infection (OR 2.032, 95% CI
1.209–3.414, P= 0.007).
Table 2. Univariate and multivariate analysis of risk factors associated with moderate–severe steatosis (Z10%) in 340 patients with chronic
hepatitis B and genotype 1 chronic hepatitis C
Variable Steatosiso 10% SteatosisZ10%
Univariate analysis
P value
Multivariate analysis
OR (95% CI) P value
Chronic hepatitis B (n= 170)
n= 117 n= 53
Age (years) 37.4 13.9 46.6 12.1 o 0.001 1.043 (1.011–1.076) 0.009
Gender
Male vs. female 77/40 44/9 0.02 0.298 (0.111–0.805) 0.01
Virological status
HBeAg/anti-HBe 24/93 4/49 o 0.001 0.710 (0.198–2.551) 0.60
Body mass index (kg/m2) 24.9 3.1 26.9 3.2 o 0.001 1.136 (1.005–1.284) 0.04
Insulin resistance (HOMA42.7)
Absent/present 98/19 28/25 o 0.001 3.815 (1.700–8.560) 0.001
Genotype 1 chronic hepatitis C (n= 170)
n= 104 n= 66
Age (years) 41.311.0 44.48.9 0.05 1.019 (0.985–1.054) 0.28
Body mass index (kg/m2) 25.13.5 26.93.5 o 0.001 1.146 (1.034–1.271) 0.009
Alanine aminotransferase (IU) 86.479.0 112.795.6 0.05 1.003 (0.999–1.007) 0.16
Insulin resistance (HOMA42.7)
Absent/present 73/31 27/39 o 0.001 2.761 (1.386–5.500) 0.004
14 patients were anti-HDV positive.
HOMA, homeostasis model assessment.
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Factors associated with moderate–severe
necroinflammatory activity
Multivariate logistic regression analysis showed that old-
er age (OR 1.078, 95% CI 1.039–1.118, Po 0.001), high
Log10 HBV-DNA (OR 1.705, 95% CI 1.187–2.451,
P= 0.004) and higher ALT levels (OR 1.025, 95% CI
1.012–1.038, Po 0.001) were independently linked to
moderate–severe necroinflammatory activity in CHB
patients. After the exclusion of 28 HBeAg-positive pa-
tients we obtained results similar to the exclusion of 14
anti-HDV-positive patients (data not shown).
In patients with CHC, by multivariate analysis we
confirmed high ALT levels (OR 1.020, 95% CI
1.008–1.032, P= 0.001) as the only variables indepen-
dently linked to moderate–severe necroinflammatory
activity.
Factors associated with severe fibrosis
The univariate and multivariate comparison of variables
between patients with and without severe fibrosis
(Scheuer scoreZ3) is reported in Table 4 for both HBV
and HCV patients. Multivariate logistic regression analy-
sis (Table 4, top) showed that the following features were
independently linked to severe fibrosis in HBV patients:
older age (OR 1.050, 95% CI 1.009–1.093, P= 0.01),
steatosis 4 10% (OR 4.375, 95% CI 1.749–10.943,
P= 0.002) and moderate–severe necroinflammatory ac-
tivity (OR 8.187, 95% CI 2.103–31.875, P= 0.002). After
the exclusion of 28 HBeAg-positive patients we obtained
results similar to the exclusion of 14 anti-HDV-positive
patients (data not shown).
In patients with CHC, older age (OR 1.080, 95% CI
1.028–1.136, P= 0.002), IR (OR 2.640, 95% CI
1.110–6.281, P= 0.02), steatosis 4 10% (OR 3.375,
95% CI 1.394–8.171, P= 0.007) and moderate–severe
necroinflammatory activity (OR 8.988, 95% CI
1.853–43.593, P= 0.006) were independently associated
with severe fibrosis by multivariate logistic regression
analysis (Table 4, bottom).
Discussion
In our study, we found a high prevalence (about 40%) of
histological steatosis in HBV patients, similar to that
observed in a matched control group of HCV-infected
subjects. Our data agree with different clinical studies on
the high prevalence of steatosis in HCV infection (4, 5,
34, 45, 46). In contrast, literature data (8–30) reported a
high range (4.5–71%) in steatosis prevalence in HBV
patients, probably because of the differences in demo-
graphical, clinical, biochemical, anthropometrical and
metabolic characteristics of studied populations. How-
ever, it is noteworthy to emphasize that we found this
high prevalence in a homogeneous cohort of HBV and
HCV patients at low risk for steatosis, because nondrin-
kers, with a mean age of 40 years, and with a low rate of
obesity, even if largely overweight.
According to different clinical evidences in HCV (5,
45, 46), and to two recent studies on HBV patients (14,
22), we identified in higher BMI and in IR, the most
important factors independently associated with steato-
sis in both the two groups, confirming that metabolic
factors are very relevant in the pathogenesis of steatosis
in both these settings of patients. However, nevertheless
the lack of association between viral load and steatosis
probably because of the fluctuating levels of viremia in
HBV and HCV infection, the higher observed steatosis
prevalence in both HCV and HBV patients compared
with those of NAFLD in the general population (47),
Table 3. Univariate and multivariate analysis of risk factors associated with insulin resistance in 340 patients with chronic hepatitis B and
genotype 1 chronic hepatitis C
Variable
No insulin resistance
(HOMA  2.7)
n= 226
Insulin resistance
(HOMA4 2.7)
n= 114
Univariate
analysis
P value
Multivariate
analysis
OR (95% CI) P value
Age (years) 39.4 12.4 45.311.3 o 0.001 1.016 (0.992–1.040) 0.19
Gender
Male vs. female 159/67 83/31 0.63 –
Body mass index (kg/m2) 25.1 3.1 26.83.7 o 0.001 1.108 (1.023–1.201) 0.01
Alanine aminotransferase (IU) 100.3 100.9 98.671.6 0.87 –
Cholesterol (mg/dl) 180.4 41.3 176.042.1 0.39 –
Triglycerides (mg/dl) 96.5 42.8 117.578.4 0.002 1.006 (1.001–1.011) 0.02
Aetiology
HCV vs. HBV 100/126 70/44 0.002 2.032 (1.209–3.414) 0.007
Histology at biopsy
Steatosis
o10% vs.Z10% 171/55 50/64 o 0.001 2.431 (1.420–4.164) 0.001
Fibrosis
1–2 vs. 3–4 191/35 65/49 o 0.001 2.636 (1.415–4.912) 0.002
Grade of inflammation
1 vs. 2–3 75/151 21/93 0.004 1.432 (0.764–2.685) 0.26
HCV, hepatitis C virus; HBV, hepatitis B virus.
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suggests a potential additive direct role of both HBVand
HCV in steatosis induction. Different lines of evidences
clearly demonstrated that HCV is able to promote liver
fatty accumulation (2, 46) with some differences accord-
ing to viral genotype. In fact in G1 CHC, hepatic fat
content is associated with clinical risk factors for NAFLD
(45), and it is not responsive to antiviral therapy (48).
Conversely, in G3 CHC, steatosis is more prevalent and
severe (49, 50), correlates with the level of HCV replica-
tion (51, 52), does not affect the severity of fibrosis (53),
disappears in patients with sustained virological response
to antivirals, and re-occurs after viral relapse (54).
Some recent experimental evidences (55–57) also
suggested that HBV, via HBx, is able to directly induce
steatosis via LXR, Srebp and PPAR g activation.
In this study, we also found that CHB patients,
compared with sex-, age- and BMI-matched CHC sub-
jects, had a significant lower rate of diabetes and IR.
Different lines of evidences already reported a lower
prevalence of diabetes in CHB patients compared with
CHC subjects (58). Instead contrasting results, in popu-
lations different for baseline demographical, anthropo-
metric and histological characteristics, reported similar
or lower IR rate in HBV patients compared with HCV
subjects (14, 29, 30, 34). Interestingly, we not only
confirmed the association between metabolic risk factors,
such as high BMI and triglyceride levels, and IR in both
CHB (26, 28, 36) and CHC patients (5), but also
identified in HCV infection an independent risk factors
for IR presence. These data add further evidences on a
direct role of HCV in induction of IR via interference
with insulin signalling (2), and confirms recent clinical
data in Asiatic populations (26, 28) that did not observe
any relation between HBV infection and IR. However
further experimental and clinical data are needed to
definitively rule out the potential interference of HBV
with insulin signaling.
In patients with CHB and CHC, several host and viral
factors have been associated with the rate of fibrosis
progression, which finally decides the prognosis of pa-
tients, leading over the years to the ultimate development
of cirrhosis. In our study, we observed that liver necroin-
flammatory activity and metabolic factors were linked to
fibrosis in both CHC and CHB. In particular, in line with
literature data, in CHB we highlighted the important role
of viral load to induce liver necroinflammation leading
to fibrosis (59). This direct association between liver
damage and viral load was not observed among CHC
Table 4. Univariate and multivariate analysis of risk factors associated with severe fibrosis (F3–F4) in 340 patients with chronic hepatitis B and
with genotype 1 chronic hepatitis C
Variable
Mild–moderate fibrosis
(Scheuer score 1–2)
Severe fibrosis
(Scheuer score 3–4)
Univariate analysis
P value
Multivariate analysis
OR (95% CI) P value
Chronic hepatitis B (n= 170)
n= 126 n= 44
Age (years) 37.0 13.6 49.4 10.8 o 0.001 1.050 (1.009–1.093) 0.01
Virological status
HBeAg/anti-HBe 26/100 2/42 0.01 0.287 (0.050–1.641) 0.16
Insulin resistance (HOMA42.7)
Absent/present 104/22 22/22 o 0.001 2.076 (0.821–5.245) 0.12
Histology at biopsy
Steatosis
o 10% vs.Z10% 100/26 17/27 o 0.001 4.375 (1.749–10.943) 0.002
Grade of inflammation
1 vs. 2–3 50/25 3/42 o 0.001 8.187 (2.103–31.875) 0.002
Genotype 1 chronic hepatitis C (n= 170)
n= 130 n= 40
Age (years) 40.6 10.2 48.8 8.2 0.002 1.080 (1.028–1.136) 0.002
Gender
Male vs. female 86/44 35/5 0.009 0.329 (0.103–1.045) 0.06
Insulin resistance (HOMA42.7)
Absent/present 87/43 13/27 o 0.001 2.640 (1.110–6.281) 0.02
Histology at biopsy
Steatosis
o 10% vs.Z10% 89/41 15/25 o 0.001 3.375 (1.394–8.171) 0.007
Grade of inflammation
1 vs. 2–3 41/89 2/38 o 0.001 8.988 (1.853–43.593) 0.006
14 patients were anti-HDV positive.
HOMA, homeostasis model assessment.
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patients, where only one retrospective analysis of six trials
on G1 CHC patients underwent antiviral therapy, identi-
fied in liver inflammation a factor associated with HCV-
RNA levels (60). Regarding the role of metabolic factors
in promotion of liver fibrosis we confirmed the indepen-
dent association of both IR and steatosis with fibrosis
severity among CHC patients (4, 5). Similarly, among
CHB patients, to our knowledge, this is the first study to
provide evidence of an independent association between
steatosis and fibrosis severity. Contrasting results ob-
tained in other works investigating the potential associa-
tion between fibrosis severity and steatosis in CHB
(13–17, 19–22, 24, 25, 27, 28) may be explained by
differences in the geographical origin and demographical
characteristics of the patients, in the baseline severity of
liver disease, and in the number of alcohol abusers. There
was also a considerable heterogeneity in the methods for
quantifying steatosis on liver biopsy, as well as in the
cut-offs of steatosis used for statistical analyses among
the different studies evaluating the impact of steatosis.
However, our results about the association between
steatosis and fibrosis severity in HBV patients, agree with
growing evidences, in other clinical setting such as CHC
and NAFLD, about the relevant role of liver fat accumu-
lation in favouring disease progression (4, 53) via
enhancement of oxidative stress that may induce both
proinflammatory cytokines production and hepatic stel-
late cell activation, ultimately responsible of disease
progression (61).
Instead, in our study, IR was not directly associated
with severe fibrosis in CHB, as was observed in two
recent studies on Asiatic population (31, 37), where
patients were different for demographical, ethnical and
virological characteristics. However, we do not rule out
that IR could have an important role in liver disease
progression, also in CHB, via inducing liver fat accumu-
lation, as observed in our study.
The main limitation of this study, as well as of other
cross-sectional studies, lies in its inability to analyse the
temporal relationship among IR, steatosis and fibrosis.
Lack of data on waist circumference, on presence of
metabolic syndrome and on other potential confounders,
such as increase in profibrogenic cytokines and adipocy-
tokines, could also affect the interpretation of results. In
addition, we cannot exclude the possibility that patients
who falsely deny abuse of alcohol may be responsible for
the observed prevalence of fibrosis and steatosis. A
further methodological issue is the potential limit of
external validity to new populations and settings. Our
study included a cohort of nondrinking European pa-
tients, with a low prevalence of obesity, who were
enrolled in a tertiary referral center for liver disease,
limiting the broad application of the results.
In conclusion, this study shows that: (i) nondrinker
patients with CHB had a high prevalence of steatosis,
similar to that observed in matched CHC controls, and
independently associated in both the two groups to high
BMI and IR; (ii) CHB subjects were less insulin resistant
than CHC individuals, considering HCV an additional
risk factor for IR; (iii) both steatosis and IR in CHC, and
only steatosis in CHB, especially together with hepatic
necroinflammation, are independently associated with
fibrosis severity. All these results therefore suggest the
necessity to validate the potential role of insulin sensitiz-
ing approaches (behaviour therapy and or pharmacolo-
gical treatment) together standard antiviral therapy, as
instruments able to interfere with natural history of CHB
and CHC.
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